Humanigen Inc (HGENQ)

[DonDonDonDon]

Humanigen Resumes Clinical Trials for Antibody Treatment Targeting Cytokine Storm

https://www.benzinga.com/general/biotech/21/11/24323400/these-biotech-companies-are-attempting-to-use-improved-antibody-technology-in-the-fight-to-eradic#/.YaUWzGg4a9I.twitter

One of the major risk factors in COVID-19 patients is the threat of cytokine storm, an inflammatory condition that occurs when an overworked immune system starts attacking its own body as it tries to fight the virus.

Humanigen Inc. HGEN -1.64% has been working hard to develop an antibody treatment that could prevent cytokine storms from happening or minimize the damage when they do. It does this by targeting the cytokines themselves.

While the FDA rejected Humanigen’s request for emergency use authorization last month, it invited the company to apply again when it had more clinical data available. Despite the setback, ongoing trials continue to study the potential benefits of the antibody treatment, and the company is working to get authorization in the United Kingdom and elsewhere.